US009409858B2

(12) **United States Patent**
Sotomayor et al.

(10) **Patent No.: US 9,409,858 B2**
(45) **Date of Patent: Aug. 9, 2016**

(54) **SELECTIVE HISTONE DEACTYLASE 6 INHIBITORS**

(71) Applicants: **H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.**, Tampa, FL (US); **BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS**, Urbana, IL (US)

(72) Inventors: **Eduardo M. Sotomayor**, Tampa, FL (US); **Joel Bergman**, Chicago, IL (US); **Alan Kozikowski**, Chicago, IL (US); **Karrune Veeraprasert Woan**, Gainesville, FL (US); **Alejandro V. Villagra**, Tampa, FL (US)

(73) Assignees: **H. Lee Moffitt Cancer Center and Research Institute, Inc.**, Tampa, FL (US); **Board of Trustees of the University of Illinois**, Urbana, IL (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/383,418**

(22) PCT Filed: **Mar. 7, 2013**

(86) PCT No.: **PCT/US2013/029521**

§ 371 (c)(1),
(2) Date: **Sep. 5, 2014**

(87) PCT Pub. No.: **WO2013/134467**

PCT Pub. Date: **Sep. 12, 2013**

(65) **Prior Publication Data**

US 2015/0056213 A1 Feb. 26, 2015

Related U.S. Application Data

(60) Provisional application No. 61/715,379, filed on Oct. 18, 2012, provisional application No. 61/674,942, filed on Jul. 24, 2012, provisional application No. 61/651,896, filed on May 25, 2012, provisional application No. 61/651,595, filed on May 25, 2012, provisional application No. 61/648,946, filed on May 18, 2012, provisional application No. 61/618,150, filed on Mar. 30, 2012, provisional application No. 61/607,803, filed on Mar. 7, 2012.

(51) **Int. Cl.**

C07C 275/28	(2006.01)
A61K 31/505	(2006.01)
A61K 31/44	(2006.01)
A61K 31/4045	(2006.01)
A61K 31/167	(2006.01)
C07D 239/42	(2006.01)
C07D 213/75	(2006.01)
C07D 209/14	(2006.01)
C07C 275/34	(2006.01)
A61K 45/06	(2006.01)
A61K 31/422	(2006.01)
A61K 31/437	(2006.01)
A61K 31/454	(2006.01)
A61K 31/69	(2006.01)
A61K 38/00	(2006.01)

(52) **U.S. Cl.**

CPC ***C07C 275/28*** (2013.01); ***A61K 31/167*** (2013.01); ***A61K 31/4045*** (2013.01); ***A61K 31/422*** (2013.01); ***A61K 31/437*** (2013.01); ***A61K 31/44*** (2013.01); ***A61K 31/454*** (2013.01); ***A61K 31/505*** (2013.01); ***A61K 31/69*** (2013.01); ***A61K 45/06*** (2013.01); ***C07C 275/34*** (2013.01); ***C07D 209/14*** (2013.01); ***C07D 213/75*** (2013.01); ***C07D 239/42*** (2013.01); *A61K 38/00* (2013.01)

(58) **Field of Classification Search**

CPC .. C07C 275/28; C07C 275/34; C07D 209/14; C07D 239/42; C07D 213/75

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2003/0070691 A1 4/2003 Giletto et al.
2007/0066646 A1 * 3/2007 Clauzel A61K 31/165 514/310

(Continued)

FOREIGN PATENT DOCUMENTS

WO 2006017216 A1 2/2006
WO 2012178208 A2 12/2012

OTHER PUBLICATIONS

Aldana-Masangkay et al.,The role of HDAC6 in cancer, J Biomed Biotechnol 2011:875824, 2010.

(Continued)

Primary Examiner — Sudhakar Katakam

(74) *Attorney, Agent, or Firm* — Meunier Carlin & Curfman LLC

(57) **ABSTRACT**

Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula (I). Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.

(I)



22 Claims, 38 Drawing Sheets